VERADIGM INC (MDRX)
(Delayed Data from OTC)
$9.65 USD
-0.05 (-0.52%)
Updated Jul 29, 2024 03:59 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDRX 9.65 -0.05(-0.52%)
Will MDRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDRX
Veradigm (MDRX) to Acquire AI Service Provider ScienceIO
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
MDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence
Braze, Inc. (BRZE) Reports Q3 Loss, Tops Revenue Estimates
Veradigm's (MDRX) New Offering to Enhance Patient Engagement
Other News for MDRX
Black Book ranks Veradigm Payer Analytics the #1 Overall Payer Analytics Solutions Vendor in 2024
Veradigm Payerpath Rated Highest in Client Satisfaction
Veradigm Explores Strategic Options, Reaffirms 2024 Outlook
Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance
Veradigm Announces Leadership Updates